Biotinylated Human EGFRVIII on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human EGFRVIII is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human EGFRVIII, His Tag at 0.5 μg/mL (100 μL/Well) on streptavidin (5 μg/mL) precoated plate. Dose response curve for Anti-EGFR VIII Anitibody, hFc Tag with the EC50 of 4.8ng/mL determined by ELISA (QC Test).
Use Biotinylated Human EGFRVIII, His Tag protein to detect the expression rate of Anti-EGFRVIII-CAR positive cell. 293T cells and anti-EGFRVIII CAR-293T cells were incubated with Biotinylated human EGFR VIII-His Tag. Non-transfected 293T cells and Biotinylated protein control were used as negative control. SA-PE was used to evaluate the binding activity of Biotinylated Human EGFR VIII.
The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene amplification frequently contain EGFR gene rearrangements, with the most common extracellular domain mutation being EGFRvIII. This mutation leads to a deletion of exons 2-7 of the EGFR gene and renders the mutant receptor incapable of binding any known ligand.
